Global Cell Therapy Market—Companies to Action, 2018

A Collaborative Business Model With Focus on Stem Cells, Chimeric Antigen Receptor T (CAR-T) Cells and Combination Therapies Will Propel Market Growth
Share this:
Published: 11 Mar 2019

The global pharmaceutical industry is continuously evolving. with the rising need for novel therapies in the ever-changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as continuously growing number of cancer cases, market needs are shifting from traditional, small molecules to novel, large-molecule therapies, with cell therapies dominating the space. The study on the "Global Cell Therapy Market, 2018, Companies to Action” presents an overview of the global cell therapy landscape, with an emphasis on the key game-changing companies disrupting this market. The study highlights the emerging companies across regions that support the development and manufacturing of novel cell therapies. With the changing market landscape, big pharma and biopharma participants, are looking toward the adoption of a collaborative business approach by either entering into co-development and/or co-commercialization agreements or acquiring smaller, niche participants so as to achieve a competitive advantage with respect to a specific therapy area or technology. The study also delves into some of the leading strategies adopted by market participants in order to succeed in this highly dynamic market. In addition to the above-mentioned strategic analysis, information such as risk sharing and fast to market business models of some of the emerging business models across the cell therapy market is also provided.



Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..